Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Sellas Life Sciences Group Inc (SLS)

Sellas Life Sciences Group Inc (SLS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 86,653
  • Shares Outstanding, K 56,268
  • Annual Sales, $ 0 K
  • Annual Income, $ -37,340 K
  • 60-Month Beta 2.35
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A
Trade SLS with:

Options Overview Details

View History
  • Implied Volatility 179.65% ( +19.70%)
  • Historical Volatility 121.84%
  • IV Percentile 44%
  • IV Rank 18.35%
  • IV High 789.77% on 06/23/23
  • IV Low 42.55% on 11/02/23
  • Put/Call Vol Ratio 0.21
  • Today's Volume 797
  • Volume Avg (30-Day) 4,913
  • Put/Call OI Ratio 0.02
  • Today's Open Interest 107,516
  • Open Int (30-Day) 107,468

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/24
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year -0.47
  • Growth Rate Est. (year over year) +212,653.19%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.9600 +57.29%
on 03/26/24
1.7200 -12.21%
on 04/23/24
+0.4700 (+45.19%)
since 03/25/24
3-Month
0.4986 +202.85%
on 01/26/24
1.7200 -12.21%
on 04/23/24
+1.0031 (+197.89%)
since 01/25/24
52-Week
0.4986 +202.85%
on 01/26/24
1.9140 -21.11%
on 07/12/23
+0.1200 (+8.63%)
since 04/25/23

Most Recent Stories

More News
Galena Biopharma, Inc. (SLS) Could Find a Support Soon, Here's Why You Should Buy the Stock Now

Galena Biopharma, Inc. (SLS) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement...

SLS : 1.5300 (-0.65%)
GenFleet Therapeutics to Present Data from Phase I Trial of GFH009 Monotherapy at the 2022 Annual Meeting of American Society of Hematology (ASH)

/PRNewswire/ -- GenFleet Therapeutics, a clinical-stage biotechnology company focusing on cutting-edge therapies in oncology and immunology, today announced...

SLS : 1.5300 (-0.65%)
SELLAS Life Sciences’ GFH009 Demonstrates Cancer Cell Growth Inhibition in Preclinical In Vitro Studies in Solid Cancer and Acute Myeloid Leukemia Cell Lines

- Results Demonstrate Significant Anti-Tumor Effects on All Selected Cell Lines - - In Three of the Four Cell Lines, GFH009 Inhibited Cancer Growth by 90...

SLS : 1.5300 (-0.65%)
SELLAS Life Sciences Adds Once-a-Week Dose Cohort in Ongoing Phase 1 Clinical Trial with its Highly Selective CDK9 Inhibitor GFH009

The Company Continues to Evaluate Optimal Dosing for Patients with Acute Myeloid Leukemia and Lymphoma in Preparation for Phase 2...

SLS : 1.5300 (-0.65%)
SELLAS Life Sciences Provides Clinical Update for GFH009 Ongoing Phase 1 Clinical Trial

- No Dose-Limiting Toxicities Observed in Lymphoma and Acute Myeloid Leukemia Patients at All Dose Levels Studied To-Date - - Early Indications of...

SLS : 1.5300 (-0.65%)
SELLAS Life Sciences Reports Encouraging Updated Clinical Data Indicating Increased Survival from Ongoing Phase 1 Mesothelioma Study of Galinpepimut-S Combined with Opdivo

Median Overall Survival of 45.7 Weeks for Patients Treated With Combination Therapy for at Least One Month; Median Overall Survival in Relapsed/Refractory...

SLS : 1.5300 (-0.65%)
SELLAS Life Sciences to Present at the JMP Securities Life Sciences Conference on June 15th

NEW YORK, June 02, 2022 (GLOBE NEWSWIRE) -- (NASDAQ: SLS) ("SELLAS" or the “Company”), a late-stage clinical biopharmaceutical company focused on the...

SLS : 1.5300 (-0.65%)
SELLAS Reports Preliminary Data Showing Clinical Benefit from Phase 1/2 Clinical Trial of Galinpepimut-S (GPS) in Combination with Keytruda® in Patients with WT1+ Advanced Ovarian Cancer

- Overall Response Rate of 7.7 percent is similar to checkpoint inhibitors alone - - Disease Control Rate for GPS combination (GPS plus Keytruda) is...

SLS : 1.5300 (-0.65%)
SELLAS Life Sciences Reports First Quarter 2022 Financial Results and Provides Business Update

- Enhanced Pipeline with New Asset, GFH009, an In-licensed Next-Generation, Highly Selective CDK9 Inhibitor - - $25 Million of Gross Proceeds from Capital...

SLS : 1.5300 (-0.65%)
SELLAS Life Sciences Launches Expanded Access Program for Galinpepimut-S

Physicians To Have Pre-Approval/Expanded Access to Galinpepimut-S (GPS) for Treatment of Patients with Acute Myeloid Leukemia (AML)...

SLS : 1.5300 (-0.65%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Strengthening short term outlook on maintaining the current direction.

See More Share

Business Summary

SELLAS Life Sciences Group is a development-stage biopharmaceutical company. It focused on novel cancer immunotherapeutics for cancer indications. The company's product candidate, galinpepimut-S, is licensed from Memorial Sloan Kettering Cancer Center and targets the Wilms Tumor 1 protein, which is present...

See More

Key Turning Points

3rd Resistance Point 1.7967
2nd Resistance Point 1.7133
1st Resistance Point 1.6267
Last Price 1.5300
1st Support Level 1.4567
2nd Support Level 1.3733
3rd Support Level 1.2867

See More

52-Week High 1.9140
Last Price 1.5300
Fibonacci 61.8% 1.3733
Fibonacci 50% 1.2063
Fibonacci 38.2% 1.0393
52-Week Low 0.4986

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar